AUBURNDALE, Mass. -- (BUSINESS WIRE) -- Vascular Nanotransfer Technologies (“VNT”) (www.vnanotech.com), an emerging medical technology company that has developed an innovative platform resulting in a proprietary Drug Coated Balloon (“DCB”), is featured in today’s issue of The Sentinel, published by OneMedPlace.
About Vascular Nanotransfer Technologies (“VNT”)
Privately held VNT, based in Auburndale, Mass., is developing Drug-Coated Balloons (DCB) that are designed to be a more precise delivery vehicle and be the standard treatment of choice for vascular atherosclerosis as well as non-vascular applications.
CAUTION: VNT’s DCBs are not approved for sale.